Targets › IL2RB
12 programs from 12 companies in 46 trials: 21 Phase 2, 21 Phase 1, 4 Phase 3; Oncology, Metabolic and endocrine, Immunology; next expected readout Nov 2026.
Receptor for interleukin-2. This beta subunit is involved in receptor mediated endocytosis and transduces the mitogenic signals of IL2. (UniProt, P14784)
Open in Phaseline: the race on IL2RB, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| ImmunityBio | Nogapendekin Alfa Inbakicept (N803) Interleukin-15 receptor agonist | IL2RG, IL2RB, IL15RA | Phase 3 | NSCLC Stage IV; Long COVID; Platinum-resistant Ovarian Cancer; Relapsed B-Cell Non Hodgkin Lymphoma … | Mar 2027 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Daclizumab (CD25) Interleukin-2 receptor inhibitor | IL2RA, IL2RG, IL2RB | Phase 3 | Graft Versus Host Disease | May 2028 |
| CellTrans | Basiliximab Interleukin-2 receptor inhibitor | IL2RA, IL2RG, IL2RB | Phase 3 | Type 1 Diabetes Mellitus; Renal Transplant Rejection; Recurrent Hodgkin Lymphoma; Acute Lymphoblastic Leukemia | – |
| Dana-Farber Cancer Institute | Aldesleukin Interleukin-2 receptor agonist | IL2RA, IL2RG, IL2RB | Phase 2 | Chronic Graft-versus-host Disease; Acute Myeloid Leukemia; Platinum-resistant Ovarian Cancer; Chronic Graft Versus Host Disease | Nov 2026 |
| Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Aldesleukin Interleukin-2 receptor agonist | IL2RA, IL2RG, IL2RB | Phase 2 | Stage IV Colorectal Cancer; Head Neck Tumors; Mesothelioma, Malignant | Dec 2026 |
| M.D. Anderson Cancer Center | Aldesleukin Interleukin-2 receptor agonist | IL2RA, IL2RG, IL2RB | Phase 2 | Melanoma; Metastatic Melanoma; Metastatic Malignant Neoplasm in the Lung | Oct 2027 |
| Assistance Publique - Hôpitaux de Paris | Aldesleukin (ILT-101) Interleukin-2 receptor agonist | IL2RA, IL2RG, IL2RB | Phase 2 | Type 1 Diabetes | Nov 2027 |
| AgonOx | DP CD8 TIL KD Interleukin-2 receptor agonist | IL2RA, IL2RG, IL2RB | Phase 1 | HNSCC | Dec 2026 |
| Sanofi | Pegenzileukin IL-2R beta/gamma agonist | IL2RG, IL2RB | Phase 1 | Plasma Cell Myeloma Refractory | Sep 2027 |
| National Cancer Institute (NCI) | Recombinant Human Interleukin-15 (rhIL-15) Interleukin-15 receptor agonist | IL2RG, IL2RB, IL15RA | Phase 1 | Neuroblastoma | Jun 2028 |
| H. Lee Moffitt Cancer Center and Research Institute | Interleukin-2 (IL-2) Cytokine to support TIL expansion and activation | IL2RA, IL2RB, IL2RG | Phase 1 | Lymphocytes | Sep 2029 |
| Alexander B Olawaiye, MD | Denileukin Diftitox (E7777) Elongation factor 2 inhibitor; Interleukin-2 receptor binding agent | EEF2, IL2RA, IL2RG, IL2RB | Phase 1 | Epithelial Ovarian Cancer | May 2030 |
Acute Myeloid Leukemia (3) Platinum-resistant Ovarian Cancer (2) Long COVID (2) Melanoma (1) Metastatic Melanoma (1) Metastatic Malignant Neoplasm in the Lung (1) Plasma Cell Myeloma Refractory (1) Chronic Graft-versus-host Disease (1) Chronic Graft Versus Host Disease (1) Epithelial Ovarian Cancer (1) NSCLC Stage IV (1) Relapsed B-Cell Non Hodgkin Lymphoma (1)
mixed (7), protein or peptide (4), small molecule (1)
M.D. Anderson Cancer Center (1) Sanofi (1) Dana-Farber Cancer Institute (1) Alexander B Olawaiye, MD (1) ImmunityBio (1) Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS (1) National Cancer Institute (NCI) (1) Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1) Assistance Publique - Hôpitaux de Paris (1) H. Lee Moffitt Cancer Center and Research Institute (1) AgonOx (1) CellTrans (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.